Human IL-2 R beta, Fc Tag (SPR verified) (Cat. No. ILB-H5253) captured on CM5 chip via anti-human IgG Fc antibody, can bind Human IL-15, Tag Free (Cat. No. IL5-H4117) with an affinity constant of 9.5 nM as determined in a SPR assay (Biacore T200) (QC tested).
Loaded Human IL-2 R beta, Fc Tag (SPR verified) (Cat. No. ILB-H5253) on Protein A Biosensor, can bind Human IL-15, Tag Free (Cat. No. IL5-H4117) with an affinity constant of 10.2 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.